USA. Sativex cannabis spray gets USA fast-track approval for cancer pain trials

"The award of Fast Track designation for Sativex represents important recognition by the FDA of the potential of this medicine to address significant unmet needs in the treatment of cancer pain," said Justin Gover who is GW's Chief Executive Officer. "Sativex is the only non-opioid treatment currently in Phase 3 development for patients who do not respond to, or experience negative side effects with opioid medications. We are fully committed to delivering the first FDA-approved cannabinoid medicine for these patients who currently have nowhere else to turn.”
This is great news for medical marijuana, not only does it infer that the official medical establishment is starting to understand the role of cannabis for cancer treatment. But it also indicates that Governments are starting to accept that cannabis really does have other important medical uses without the nasty side effects of other prescription treatments.
More information is here http://www.marketwatch.com/story/gw-pharmaceuticals-announces-that-sativex-receives-fast-track-designation-from-fda-in-cancer-pain-2014-04-28